Empirical antifungal treatment for diagnosed and undiagnosed invasive fungal disease in patients with hematologic malignancies

References

• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21
   PubMed Web of Science ®Google Scholar
• Fung M, Kim J, Marty FM, et al. Meta-analysis and cost comparison of empirical versus pre-emptive antifungal strategies in hematologic malignancy patients with high-risk febrile neutropenia. PLoS One 2015;10:e0140930
   PubMed Web of Science ®Google Scholar
• Sun Y, Huang H, Chen J, et al. Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China. Tumour Biol 2015;36:757-67
   PubMedGoogle Scholar
• Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91:1068-75
   PubMed Web of Science ®Google Scholar
• Lortholary O, Gangneux JP, Sitbon K, et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clin Microbiol Infect 2011;17:1882-9
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Strenger V, Buzina W, et al. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. J Antimicrob Chemother 2012;67:2029-33
   PubMed Web of Science ®Google Scholar
• De Pascale G, Tumbarello M. Fungal infections in the ICU: advances in treatment and diagnosis. Curr Opin Crit Care 2015;21:421-9
   PubMed Web of Science ®Google Scholar
• Guigue N, Lardeux S, Alanio A, et al. Importance of operational factors in the reproducibility of Aspergillus galactomannan enzyme immune assay. PLoS One 2015;10:e0124044
   PubMed Web of Science ®Google Scholar
• Auberger J, Lass-Flörl C, Ulmer H, et al. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 2008;88:508-15
   PubMed Web of Science ®Google Scholar
• Muhlemann K, Wenger C, Zenhausern R, et al. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005;19:545-50
   PubMed Web of Science ®Google Scholar
• Tsitsikas DA, Morin A, Araf S, et al. Impact of the revised (2008) EORTC/MSG definitions for invasive fungal disease on the rates of diagnosis of invasive aspergillosis. Med Mycol 2012;50:538-42
   PubMed Web of Science ®Google Scholar
• Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 2006;91:986-9
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study – Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007;45:1161-70
   PubMed Web of Science ®Google Scholar
• Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009;48:265-73
   PubMed Web of Science ®Google Scholar
• Orasch C, Weisser M, Mertz D, et al. Comparison of infectious complications during induction/consolidation chemotherapy versus allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2010;45:521-6
   PubMed Web of Science ®Google Scholar
• Kume H, Yamazaki T, Togano T, et al. Epidemiology of visceral mycoses in autopsy cases in Japan: comparison of the data from 1989, 1993, 1997, 2001, 2005 and 2007 in Annual of Pathological Autopsy Cases in Japan. Med Mycol J 2011;52:117-27
   PubMedGoogle Scholar
• Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003;37:382-9
   PubMed Web of Science ®Google Scholar
• Erjavec Z, de Vries-Hospers HG, Laseur M, et al. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 2000;45:843-9
   PubMed Web of Science ®Google Scholar
• Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2004;39(Suppl 1):S38-S43
   PubMed Web of Science ®Google Scholar
• Marchetti O, Cordonnier C, Calandra T. Empirical anti-fungal therapy in neutropenic cancer patients with persistent fever. Eur J Canc Suppl 2007;5:11
   Google Scholar
• Ceesay MM, Sadique Z, Harris R, et al. Prospective evaluation of the cost of diagnosis and treatment of invasive fungal disease in a cohort of adult haematology patients in the UK. J Antimicrob Chemother 2015;70:1175-81
   PubMed Web of Science ®Google Scholar
• Morrissey CO, Gilroy NM, Macesic N, et al. Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014. Intern Med J 2014;44:1298-314
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042-51
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Caillot D, Cordonnier C, et al. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation. J Antimicrob Chemother 2012;67:2731-8
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17
   PubMed Web of Science ®Google Scholar
• Pagano L, Girmenia C, Mele L, et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001;86:862-70
   PubMed Web of Science ®Google Scholar
• Sun Y, Meng F, Han M, et al. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study. Biol Blood Marrow Transplant 2015;21:1117-26
   PubMed Web of Science ®Google Scholar
• Blyth CC, Gilroy NM, Guy SD, et al. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J 2014;44:1333-49
   PubMed Web of Science ®Google Scholar
• Pappas PG. Antifungal clinical trials and guidelines: what we know and do not know. Cold Spring Harb Perspect Med 2014;4:a019745
   PubMed Web of Science ®Google Scholar
• Girmenia C, Micozzi A, Piciocchi A, et al. Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. Leuk Res 2014;38:469-74
   PubMed Web of Science ®Google Scholar
• Li W, Zhao X, Gong B, et al. Impact of risk stratification on the duration of caspofungin therapy for invasive fungal disease in acute leukemic patients. Future Microbiol 2015;10:161-8
   PubMed Web of Science ®Google Scholar